Related Experiment Video
Updated: Jan 21, 2026

Analysis of mRNA Nuclear Export Kinetics in Mammalian Cells by Microinjection
Published on: December 4, 2010
TRAIL responses are enhanced by nuclear export inhibition in osteosarcoma
K L Phillips1, N Wright1, E McDermott1
1Biomolecular Sciences Research Centre, Sheffield Hallam University, Howard Street, Sheffield, S1 1AF, UK.
Abstract:
Tumour necrosis factor-related apoptosis inducing ligand (TRAIL) is a promising anti-tumour agent that induces apoptosis of malignant cells through activation of death receptors. Death receptor agonistic antibodies are in clinical trials as TRAIL-mimetics, however, along with TRAIL monotherapy, there is limited efficacy due to the rapid emergence of TRAIL resistance, or due to existing TRAIL-insensitive disease. TRAIL-sensitisers, which enhance TRAIL activity or overcome TRAIL resistance, may facilitate death receptor agonists as viable anti-tumour strategies. In this study we demonstrate that the nuclear export inhibitor Leptomycin B, is a potent in vitro TRAIL-sensitiser in osteosarcoma cell lines. Leptomycin B works synergistically with both TRAIL and death receptor 5 agonistic antibodies to induce apoptosis in TRAIL sensitive cell lines. Further, Leptomycin B sensitises TRAIL-insensitive cell lines to TRAIL and death receptor agonistic antibody mediated apoptosis. We also confirmed that aldehyde dehydrogenase (ALDH) positive cells are not resistant to the apoptotic effects of TRAIL and Leptomycin B, an important observation since ALDH positive cells can have enhanced tumorigenicity and are implicated in disease recurrence and metastasis. The nuclear export pathway in combination with death receptor agonists, is a potential therapeutic strategy in osteosarcoma and warrants further research on clinically relevant selective inhibitors of nuclear export.
Insights
Leptomycin B enhances the anti-cancer effects of TRAIL therapy in osteosarcoma. This nuclear export inhibitor overcomes TRAIL resistance and sensitizes resistant cells, offering a potential new strategy for osteosarcoma treatment.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- Tumour necrosis factor-related apoptosis inducing ligand (TRAIL) shows anti-cancer potential by inducing apoptosis.
- TRAIL resistance and TRAIL-insensitive disease limit the efficacy of TRAIL-based therapies.
- TRAIL-sensitizers are needed to enhance TRAIL activity and overcome resistance.
Purpose of the Study:
- To investigate the potential of Leptomycin B as a TRAIL-sensitizer in osteosarcoma.
- To evaluate the synergistic effects of Leptomycin B with TRAIL and death receptor agonists.
- To determine if Leptomycin B overcomes TRAIL resistance in osteosarcoma cell lines.
Main Methods:
- In vitro studies using osteosarcoma cell lines.
- Treatment with Leptomycin B, TRAIL, and death receptor 5 agonistic antibodies.
- Assessment of apoptosis induction and TRAIL sensitivity/resistance.
- Evaluation of aldehyde dehydrogenase (ALDH) positive cell response.
Main Results:
- Leptomycin B acts as a potent in vitro TRAIL-sensitizer in osteosarcoma cells.
- Leptomycin B synergizes with TRAIL and death receptor 5 agonistic antibodies to induce apoptosis.
- Leptomycin B sensitizes TRAIL-insensitive osteosarcoma cells to apoptosis.
- ALDH-positive cells are not resistant to Leptomycin B and TRAIL-induced apoptosis.
Conclusions:
- Leptomycin B is a promising TRAIL-sensitizer for osteosarcoma treatment.
- Combining nuclear export inhibition with death receptor agonists is a potential therapeutic strategy.
- Further research into selective nuclear export inhibitors is warranted for osteosarcoma therapy.
More Related Videos
Related Concept Videos
Nuclear Export
NES are of three types- the canonical 10-residue long leucine-rich signal and other...
Nuclear Export of mRNA
Nuclear Export of mRNA
Export of Mitochondrial and Chloroplast Genes
Nuclear Overhauser Enhancement (NOE)
Feedback Inhibition

